Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors

Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insuli...

Full description

Bibliographic Details
Main Authors: Jacob E. Pruett, Damian G. Romero, Licy L. Yanes Cardozo
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Endocrinology
Subjects:
polycystic ovary syndrome (PCOS)
obesity
SGLT 2 inhibitors
cardiometabolic complications
hypertension
insulin resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.951099/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.951099/full

Similar Items